Baxter International (BAX) : On Monday, The money flowed into the Baxter International (BAX) stock with an uptick to downtick ratio was recorded at 1.38. Transactions worth $29.89 million were done on upticks, confirming the buying interest in the stock. The outflow of money on downticks stood at $21.59 million. The total money flow into the stock was $8.29 million. The block trades reveal a bullish bias with an up-down ratio of 3.64. The investors are using every small weakness in the stock to accumulate it, as can be seen in the $11.99 million of block transactions on upticks. The value of block trades on downticks was $3.3 million, indicating lower selling interest. The total money flow in block trades was $8.7 million. In terms of price action, Baxter International (BAX) traded down $0.22 during the session at $46.55. Compared to the previous days closing, the stock was down only by -0.47%. For the week, the stock is -0.21%, over previous weeks closing.
Baxter International Inc. is up 8.33% in the last 3-month period. Year-to-Date the stock performance stands at 22.74%. Shares of Baxter International Inc. rose by 0.13% in the last five trading days and 4.44% for the last 4 weeks. In a related news, Almeida Jose E, CEO of Baxter International Inc had purchased 11,691 shares on May 23, 2016 in a transaction. The price per share was $42.75 and the total amount of the disclosed transaction was $499,790.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.
Baxter International (NYSE:BAX): On Mondays trading session , Opening price of the stock was $46.81 with an intraday high of $46.86. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $46.34. However, the stock managed to close at $46.55, a loss of 0.47% for the day. On the previous day, the stock had closed at $46.77. The total traded volume of the day was 2,811,905 shares.
Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.